Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price.
The AmgenNow program will provide Repatha for $239 per month — nearly 60% below the current U.S. list price — to all eligible patients, including those who are uninsured or prefer to pay out of pocket, according to an Oct. 6 news release. Program participants will not be subject to step therapy or prior authorization requirements.
The new price is the lowest among economically developed countries, the release said, and it supports the Trump administration’s effort to lower U.S. drug costs. The company plans to make AmgenNow accessible through TrumpRx, a federal website set to launch in early 2026 that will connect consumers with discounted medications.
Several drugmakers — including Pfizer, Eli Lilly, Novo Nordisk and Novartis — have launched or announced similar direct-to-consumer programs in recent months, particularly for chronic conditions, like obesity and high cholesterol. These efforts follow federal pressure on pharmaceutical companies to match lower prices found in other high-income countries.